|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000196074 |
Summary for SYCP2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000196074 | Gene symbol | SYCP2 |
| Gene name | synaptonemal complex protein 2 | |
| HGNC | 11490 | |
| Entrez ID | 10388 | |
| Gene type | protein_coding | |
| Synonyms | SYCP2|SCP2 | |
| UniProtAcc | Q9BX26 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for SYCP2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SYCP2 | 4.58e+02 | 1.26e+00 | 2.26e-01 | 5.57e+00 | 2.51e-08 | 2.19e-06 | HNSC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SYCP2 | 5.04e+02 | 3.40e+00 | 4.22e-01 | 8.06e+00 | 7.49e-16 | 9.56e-15 | HNSC |
| SYCP2 | 3.53e+02 | 2.41e+00 | 5.45e-01 | 4.42e+00 | 9.90e-06 | 5.84e-05 | BLCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SYCP2 | 2.35e+03 | 1.41e+00 | 1.35e-01 | 1.05e+01 | 9.93e-26 | 4.26e-25 | BRCA |
Top |
Sex-biased somatic mutation for SYCP2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for SYCP2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg07347645 | chr20:59932116 | CGI:chr20:59932700-59934462 | UTR,promoter,exon,gene body | 6.55e-01 | 4.55e-01 | 2.30e+00 | 2.12e-02 | 3.58e-02 | 2.01e-01 |
| BRCA | cg22214414 | chr20:59932177 | CGI:chr20:59932700-59934462 | promoter,gene body | 6.88e-01 | 4.62e-01 | 2.54e+00 | 1.12e-02 | 2.79e-02 | 2.26e-01 |
| BRCA | cg12181372 | chr20:59933068 | CGI:chr20:59932700-59934462 | promoter,gene body | 7.19e-01 | 4.62e-01 | 2.17e+00 | 2.99e-02 | 4.09e-02 | 2.56e-01 |
| LIHC | cg26690949 | chr20:59933888 | CGI:chr20:59932700-59934462 | promoter | 3.16e-01 | 4.20e-01 | -2.88e+00 | 4.02e-03 | 9.64e-03 | -1.04e-01 |
| GBM | cg26690949 | chr20:59933888 | CGI:chr20:59932700-59934462 | promoter | 2.26e-02 | 1.28e-01 | -2.26e+00 | 2.36e-02 | 3.81e-02 | -1.05e-01 |
| ESCA | cg20800536 | chr20:59933833 | CGI:chr20:59932700-59934462 | promoter | 2.63e-01 | 1.61e-01 | 2.50e+00 | 1.23e-02 | 3.01e-02 | 1.03e-01 |
| ESCA | cg02801359 | chr20:59933867 | CGI:chr20:59932700-59934462 | promoter | 3.29e-01 | 2.05e-01 | 2.32e+00 | 2.01e-02 | 3.79e-02 | 1.24e-01 |
| ESCA | cg26690949 | chr20:59933888 | CGI:chr20:59932700-59934462 | promoter | 3.02e-01 | 1.70e-01 | 2.40e+00 | 1.65e-02 | 3.50e-02 | 1.32e-01 |
| ESCA | cg25183989 | chr20:59933531 | CGI:chr20:59932700-59934462 | promoter,gene body | 5.78e-01 | 4.58e-01 | 3.06e+00 | 2.22e-03 | 8.93e-03 | 1.20e-01 |
| ESCA | cg00125414 | chr20:59934187 | CGI:chr20:59932700-59934462 | promoter | 3.06e-01 | 1.76e-01 | 2.84e+00 | 4.47e-03 | 1.55e-02 | 1.30e-01 |
| ESCA | cg14536096 | chr20:59934243 | CGI:chr20:59932700-59934462 | promoter | 3.03e-01 | 1.81e-01 | 2.12e+00 | 3.41e-02 | 4.54e-02 | 1.22e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg07347645 | chr20:59932116 | CGI:chr20:59932700-59934462 | UTR,promoter,exon,gene body | 8.37e-01 | 9.48e-01 | -3.33e+00 | 8.58e-04 | 1.59e-03 | -1.11e-01 |
| HNSC | cg23241473 | chr20:59932172 | CGI:chr20:59932700-59934462 | promoter,gene body | 7.60e-01 | 9.07e-01 | -3.87e+00 | 1.07e-04 | 2.75e-04 | -1.47e-01 |
| LUSC | cg26690949 | chr20:59933888 | CGI:chr20:59932700-59934462 | promoter | 1.22e-01 | 1.67e-02 | 2.86e+00 | 4.19e-03 | 7.14e-03 | 1.05e-01 |
| LUSC | cg06710769 | chr20:59934504 | CGI:chr20:59932700-59934462 | promoter | 2.33e-01 | 8.49e-02 | 2.25e+00 | 2.44e-02 | 2.79e-02 | 1.48e-01 |
| LUSC | cg23241473 | chr20:59932172 | CGI:chr20:59932700-59934462 | promoter,gene body | 8.36e-01 | 9.42e-01 | -4.05e+00 | 5.21e-05 | 5.63e-04 | -1.06e-01 |
| COAD | cg20800536 | chr20:59933833 | CGI:chr20:59932700-59934462 | promoter | 2.80e-01 | 1.09e-01 | 2.59e+00 | 9.47e-03 | 1.38e-02 | 1.72e-01 |
| COAD | cg00125414 | chr20:59934187 | CGI:chr20:59932700-59934462 | promoter | 2.40e-01 | 6.50e-02 | 3.08e+00 | 2.04e-03 | 4.01e-03 | 1.75e-01 |
| LIHC | cg20800536 | chr20:59933833 | CGI:chr20:59932700-59934462 | promoter | 2.60e-01 | 1.19e-01 | 2.45e+00 | 1.41e-02 | 1.65e-02 | 1.42e-01 |
| LIHC | cg06710769 | chr20:59934504 | CGI:chr20:59932700-59934462 | promoter | 3.85e-01 | 2.08e-01 | 2.84e+00 | 4.56e-03 | 6.08e-03 | 1.77e-01 |
| LIHC | cg14536096 | chr20:59934243 | CGI:chr20:59932700-59934462 | promoter | 3.41e-01 | 1.74e-01 | 2.90e+00 | 3.68e-03 | 5.03e-03 | 1.67e-01 |
| CHOL | cg12181372 | chr20:59933068 | CGI:chr20:59932700-59934462 | promoter,gene body | 8.88e-01 | 6.88e-01 | 2.88e+00 | 4.04e-03 | 1.47e-02 | 2.00e-01 |
| CHOL | cg25183989 | chr20:59933531 | CGI:chr20:59932700-59934462 | promoter,gene body | 5.95e-01 | 4.73e-01 | 2.06e+00 | 3.90e-02 | 4.26e-02 | 1.22e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg21950459 | chr20:59933021 | CGI:chr20:59932700-59934462 | promoter,gene body | 7.60e-01 | 9.70e-01 | -5.44e+00 | 5.31e-08 | 1.11e-07 | -2.10e-01 |
| BRCA | cg07347645 | chr20:59932116 | CGI:chr20:59932700-59934462 | UTR,promoter,exon,gene body | 6.55e-01 | 9.32e-01 | -1.13e+01 | 1.54e-29 | 2.12e-28 | -2.76e-01 |
| BRCA | cg23241473 | chr20:59932172 | CGI:chr20:59932700-59934462 | promoter,gene body | 6.25e-01 | 9.06e-01 | -1.02e+01 | 2.37e-24 | 1.89e-23 | -2.81e-01 |
| BRCA | cg22214414 | chr20:59932177 | CGI:chr20:59932700-59934462 | promoter,gene body | 6.88e-01 | 9.22e-01 | -9.44e+00 | 3.68e-21 | 2.20e-20 | -2.35e-01 |
| BRCA | cg12181372 | chr20:59933068 | CGI:chr20:59932700-59934462 | promoter,gene body | 7.19e-01 | 8.67e-01 | -2.59e+00 | 9.47e-03 | 1.07e-02 | -1.48e-01 |
| LIHC | cg25183989 | chr20:59933531 | CGI:chr20:59932700-59934462 | promoter,gene body | 5.83e-01 | 4.54e-01 | 3.73e+00 | 1.89e-04 | 6.25e-04 | 1.29e-01 |
Top |
Exon skipping events with PSI in TCGA for SYCP2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for SYCP2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for SYCP2 |
| TFs related to SYCP2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | ZNF141 | SYCP2 | 3.98e+00 | 9.82e-01 | 3.06e+00 | 5.89e-03 | Male-biased |
| ACC | ZNF28 | SYCP2 | 4.00e+00 | 9.85e-01 | 2.92e+00 | 3.02e-03 | Male-biased |
| PAAD | ALX1 | SYCP2 | 4.28e+00 | 9.90e-01 | 2.72e+00 | 2.13e-04 | Male-biased |
| PAAD | BARX2 | SYCP2 | 4.33e+00 | 9.91e-01 | 2.77e+00 | 2.20e-04 | Male-biased |
| PAAD | CDC5L | SYCP2 | 4.62e+00 | 9.93e-01 | 3.36e+00 | 1.11e-03 | Male-biased |
| PAAD | FOXF1 | SYCP2 | 3.89e+00 | 9.83e-01 | 2.42e+00 | 3.30e-04 | Male-biased |
| PAAD | FOXQ1 | SYCP2 | 3.94e+00 | 9.84e-01 | 2.53e+00 | 4.78e-04 | Male-biased |
| PAAD | GATA3 | SYCP2 | 4.39e+00 | 9.89e-01 | 3.31e+00 | 2.87e-03 | Male-biased |
| PAAD | HMX1 | SYCP2 | 4.19e+00 | 9.89e-01 | 2.81e+00 | 5.54e-04 | Male-biased |
| PAAD | HOXA9 | SYCP2 | 4.23e+00 | 9.89e-01 | 2.93e+00 | 8.79e-04 | Male-biased |
| PAAD | IRX3 | SYCP2 | 4.54e+00 | 9.91e-01 | 3.46e+00 | 2.88e-03 | Male-biased |
| PAAD | IRX5 | SYCP2 | 5.16e+00 | 9.90e-01 | 4.27e+00 | 7.84e-03 | Male-biased |
| PAAD | ISX | SYCP2 | 4.40e+00 | 9.92e-01 | 2.96e+00 | 4.10e-04 | Male-biased |
| PAAD | LHX3 | SYCP2 | 3.91e+00 | 9.82e-01 | 2.62e+00 | 8.80e-04 | Male-biased |
| PAAD | MEOX2 | SYCP2 | 4.01e+00 | 9.86e-01 | 2.39e+00 | 1.43e-04 | Male-biased |
| PAAD | MYNN | SYCP2 | 4.01e+00 | 9.85e-01 | 2.49e+00 | 2.53e-04 | Male-biased |
| PAAD | NEUROD1 | SYCP2 | 4.35e+00 | 9.90e-01 | 3.15e+00 | 1.51e-03 | Male-biased |
| PAAD | ONECUT3 | SYCP2 | 4.06e+00 | 9.86e-01 | 2.73e+00 | 7.25e-04 | Male-biased |
| PAAD | PAX3 | SYCP2 | 5.93e+00 | 9.91e-01 | 5.06e+00 | 8.34e-03 | Male-biased |
| PAAD | PHOX2B | SYCP2 | 4.24e+00 | 9.90e-01 | 2.76e+00 | 3.22e-04 | Male-biased |
| PAAD | POU1F1 | SYCP2 | 4.18e+00 | 9.86e-01 | 3.09e+00 | 2.63e-03 | Male-biased |
| PAAD | POU4F1 | SYCP2 | 4.00e+00 | 9.85e-01 | 2.55e+00 | 3.85e-04 | Male-biased |
| PAAD | POU4F2 | SYCP2 | 3.98e+00 | 9.85e-01 | 2.31e+00 | 1.06e-04 | Male-biased |
| PAAD | POU4F3 | SYCP2 | 4.07e+00 | 9.86e-01 | 2.66e+00 | 4.84e-04 | Male-biased |
| PAAD | PRRX1 | SYCP2 | 4.40e+00 | 9.91e-01 | 3.08e+00 | 7.96e-04 | Male-biased |
| PAAD | SOX10 | SYCP2 | 4.08e+00 | 9.87e-01 | 2.59e+00 | 3.07e-04 | Male-biased |
| PAAD | SOX8 | SYCP2 | 4.00e+00 | 9.85e-01 | 2.56e+00 | 4.12e-04 | Male-biased |
| PAAD | SOX9 | SYCP2 | 3.96e+00 | 9.84e-01 | 2.39e+00 | 1.90e-04 | Male-biased |
| PAAD | T | SYCP2 | 4.01e+00 | 9.80e-01 | 3.06e+00 | 5.31e-03 | Male-biased |
| PAAD | TWIST1 | SYCP2 | 3.91e+00 | 9.83e-01 | 2.34e+00 | 1.95e-04 | Male-biased |
| PAAD | ZKSCAN2 | SYCP2 | 3.94e+00 | 9.84e-01 | 2.37e+00 | 1.87e-04 | Male-biased |
| PAAD | ZNF175 | SYCP2 | 3.86e+00 | 9.82e-01 | 2.40e+00 | 3.59e-04 | Male-biased |
| PAAD | ZNF232 | SYCP2 | 4.27e+00 | 9.86e-01 | 3.27e+00 | 4.21e-03 | Male-biased |
| PAAD | ZNF250 | SYCP2 | 4.02e+00 | 9.86e-01 | 2.61e+00 | 4.59e-04 | Male-biased |
| PAAD | ZNF334 | SYCP2 | 3.93e+00 | 9.84e-01 | 1.91e+00 | 1.41e-05 | Male-biased |
| PAAD | ZNF337 | SYCP2 | 4.25e+00 | 9.87e-01 | 3.16e+00 | 2.54e-03 | Male-biased |
| PAAD | ZNF45 | SYCP2 | 3.91e+00 | 9.82e-01 | 2.68e+00 | 1.21e-03 | Male-biased |
| PAAD | ZNF525 | SYCP2 | 4.44e+00 | 9.92e-01 | 3.16e+00 | 1.01e-03 | Male-biased |
| PAAD | ZNF580 | SYCP2 | 4.27e+00 | 9.90e-01 | 2.52e+00 | 7.31e-05 | Male-biased |
| PAAD | ZNF716 | SYCP2 | 3.83e+00 | 9.81e-01 | 2.29e+00 | 2.25e-04 | Male-biased |
| PAAD | ZNF79 | SYCP2 | 3.82e+00 | 9.81e-01 | 1.90e+00 | 2.59e-05 | Male-biased |
| PAAD | ZNF8 | SYCP2 | 4.11e+00 | 9.85e-01 | 3.04e+00 | 2.89e-03 | Male-biased |
| PAAD | ZSCAN23 | SYCP2 | 4.21e+00 | 9.85e-01 | 3.22e+00 | 4.49e-03 | Male-biased |
| SKCM | ZNF418 | SYCP2 | 4.52e+00 | 8.91e-03 | 5.55e+00 | 9.88e-01 | Female-biased |
| SYCP2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for SYCP2 |
| RBPs related to ES in SYCP2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SYCP2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs404727 | chr20:56890378:A:G | - | -0.0651184929018197 | 0.00636864703630953 | LUAD | Female-baised eQTL |
| rs1321864 | chr20:56794071:C:T | - | 0.0663860672254828 | 0.0077600984546988 | LUAD | Female-baised eQTL |
| rs6096235 | chr20:51033173:C:T | - | 0.0626405443939204 | 0.0247315505431122 | LUAD | Female-baised eQTL |
| rs6013211 | chr20:51549470:A:T | - | 0.0463643813365095 | 0.0272241520227769 | LUAD | Female-baised eQTL |
| rs7270377 | chr20:56886844:G:A | - | 0.051138624358695 | 0.0420771272252855 | LUAD | Female-baised eQTL |
| rs6096186 | chr20:50917412:T:C | - | 0.0819787352245214 | 0.0431671795613918 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11905447 | chr20:53036314:C:T | - | 0.0892192900525487 | 0.00791367695103126 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000196074 |
| CpG Site: cg23241473 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.305106624563457 | |
| Female Effect: - | |
 | Gene ID: ENSG00000196074 |
| CpG Site: cg07347645 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.30489030254373 | |
| Female Effect: - | |
 | Gene ID: ENSG00000196074 |
| CpG Site: cg22214414 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.30489030254373 | |
| Female Effect: - | |
 | Gene ID: ENSG00000196074 |
| CpG Site: cg12181372 | |
| Position to Gene: gene,promoter | |
| Male Effect: - | |
| Female Effect: -0.486632887903856 | |
 | Gene ID: ENSG00000196074 |
| CpG Site: cg22214414 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.306770686099121 | |
| Female Effect: - | |
 | Gene ID: ENSG00000196074 |
| CpG Site: cg25183989 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.116691590438242 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg23241473 | chr20:59932172 | gene,promoter | -0.305106624563457 | 7.85293409076334e-05 | -0.3347944903033709 | 3.2498496689244313e-07 | LUAD |
| cg07347645 | chr20:59932116 | gene,exon,promoter,UTR | -0.30489030254373 | 7.98635901322736e-05 | -0.334085576114439 | 3.2479109200545916e-07 | LUAD |
| cg22214414 | chr20:59932177 | gene,promoter | -0.30489030254373 | 7.98635901322736e-05 | -0.334085576114439 | 3.2479109200545916e-07 | LUAD |
| cg22214414 | chr20:59932177 | gene,promoter | -0.306770686099121 | 8.71763211220533e-56 | -0.7924726365191268 | 3.905387346493121e-60 | LUSC |
| cg25183989 | chr20:59933531 | gene,promoter | -0.116691590438242 | 9.38003625062123e-17 | -0.5236173513407154 | 7.826116246098354e-21 | LUSC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg12181372 | chr20:59933068 | gene,promoter | -0.486632887903856 | 3.65609501363785e-11 | -0.440630542334807 | 1.5483528474106814e-13 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of SYCP2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
